RU2284828C1 - Method for treating patients with urogenital herpes-viral infection in combination with chlamydiosis - Google Patents

Abstract

FIELD: medicine, dermatovenerology.

SUBSTANCE: on establishing the diagnosis at the first stage of therapy it is necessary to prescribe derinate as 1.5%-solution per 5.0 ml intramuscularly 5 times every 48 h followed by magneto-infrared-laser impact: wave length being 0.85-0.95 mcm, impulse frequency being 50 Hz, power of light diodes radiation being 50 mW, magnetic induction corresponds to about 20-80 mTl, dosage of energetic impact ranges 0.8-1.07 J/sq. cm. Total time for procedure - 10 min. One should affect the area of thymus gland for 2 min, spleen - 2 min, inguinal lymph nodes - per 2 min, lumbosacral - 2 min. Therapy course consists of 10 daily procedures. The innovation enables to shorten therapy terms, improve quality of life in patients with urogenital herpes-viral infection in combination with chlamydiosis and increase the number of medicinal preparations for treating the above-mentioned combination of infections.

EFFECT: higher efficiency of therapy.

1 dwg, 1 ex, 2 tbl

Description

The invention relates to medicine, in particular to dermatovenerology.

Treatment of urogenital herpes virus infection is accompanied by significant difficulties, which are mainly due to the long recurrent course of the disease, the multi-focal nature of the lesions and impaired immune status of the patient’s body. Even more difficult is the treatment of urogenital herpes virus infection in combination with chlamydia.

Used drugs and agents for the treatment and prevention of urogenital herpes virus infection in combination with chlamydia often do not provide the necessary therapeutic effect, and failures in the treatment of this category of patients range from 15 to 50%. Such a sufficiently large range of fluctuations depends not only on the biological characteristics of the causative agents of these diseases, but also on the state of immunological reactivity of the patient’s body.

Currently, the closest to the invention is a method of treating infections caused by herpes simplex virus using the drug "Zovirax" (acyclovir). (Herpes-virus infection: clinical forms, pathogenesis, treatment. A guide for doctors. II Mavrov. - Kharkov: Fact, 1998. - 80 pp.).

However, the prototype has several disadvantages: frequent relapses after treatment with a combination of herpesvirus infection and chlamydia, the long term treatment of this category of patients, the immunocorrective drug derinat and the non-pharmacological method of exposure as a magneto-infrared laser are not used in the complex treatment of this category of patients.

The objective of the invention is to reduce the time, improve the quality of life of patients with urogenital herpes virus infection in combination with chlamydia, expanding the range of pharmacological and non-pharmacological agents for the treatment of this combination of infections.

The task is achieved in that for the treatment of patients with urogenital herpes virus infection in combination with chlamydia, a combination of pharmacological and non-pharmacological methods of exposure is used: the drug derinat, which has an immunocorrective effect, which is prescribed in the form of a 1.5% solution of 5.0 ml intramuscularly 5 times after 48 hours and magneto-infrared laser exposure, which has anti-inflammatory, absorbable and restorative effects:

wavelength 0.85-0.95 μm, pulse repetition rate of 50 Hz, LED radiation power of 50 mW, magnetic induction - 20-80 mT, dose of energy exposure - 0.8-1.07 J / cm, the total procedure time is 10 min. The scheme of influence on the area: thymus gland - 2 min, spleen - 2 min, inguinal lymph nodes - 2 min, lumbosacral (paravertebral) - 2 min, course - 10 daily procedures.

The invention is illustrated by the drawing: the dynamics of the immunological parameters of patients receiving treatment according to the developed scheme from the level of patients treated traditionally (which is the radius of the circle in the drawing).

The developed combined treatment technique for patients with urogenital herpes virus infection in combination with chlamydia is carried out using pharmacological and nonpharmacological methods of treatment in the complex treatment: Derinat, an immunostimulating drug that stimulates the B and T immunity, activates cells of the monocytic macrophage system, which leads to to enhance anti-infectious resistance of the body, has antioxidant, reparative and regenerative properties.

In addition to the drug, Derinat uses a non-pharmacological method of exposure as magneto-infrared laser therapy.

The method is as follows.

After establishing a clinical, topical and etymological diagnosis, derinat is prescribed in the form of a 1.5% solution of 5.0 ml intramuscularly 5 times after 48 hours and a magneto-infrared laser exposure: wavelength 0.85-0.95 μm, pulse repetition rate 50 Hz, LED radiation power of 50 mW, magnetic induction - 20-80 mT, dose of energy exposure - 0.8-1.07 J / cm ² , total procedure time - 10 min. The scheme of influence on the area: thymus gland - 2 min, spleen - 2 min, inguinal lymph nodes - 2 min, lumbosacral (paravertebral) - 2 min, course - 10 daily procedures.

To compare the results of treatment according to the proposed method, a group of patients with genital herpes in combination with chlamydia was treated according to traditional conventional methods (Table 1).

Conducted traditional treatment of patients can reduce the duration of subjective sensations to 3.2 days, the duration of the regression period of herpetic eruptions to 7.1 days and increase the period of remission of the disease to 5.5 months. After assessing the condition of patients using the system of cumulative symptom assessment, it was found that these patients had a symptom index of 4.6 points, a clinical index of 9.8 points, quality of life improved, but remained low - 5.2 points, indicating insufficient clinical effectiveness of the traditional treatment regimen.

The proposed treatment regimen was more effective, because its use allowed to reduce the duration of subjective sensations to 1.6 days, the duration of the period of regression of herpetic eruptions to 2.1 days and to increase the period of remission of the disease up to 6 months, to improve the quality of life and reduce the clinical index and symptom index.

Table 1 Clinical criteria for the course of the disease of urogenital herpes virus infection in combination with chlamydia according to the developed method and conventional traditional methods Criteria Patient groups Treated according to the method without the use of Derinat and MIL-therapy Received treatment according to the developed methodology The duration of subjective sensations during relapse (itching, burning, pain, general malaise), days 3.2 1,6 The duration of the period of regression of herpetic eruptions, days 7.1 2.1 The duration of the remission period, months 5.5 6.0 The quality of life 4.6 2.1 Symptom index 5.2 2,5 Clinical index 9.8 4.6

The revealed subjective and clinical data were confirmed by the immunological profile of patients with herpes virus infection in combination with chlamydia under the influence of treatment. It was found that during the traditional treatment, the traditional treatment normalizes the content of CD095 lymphocytes, B cells (CD22), phagocytic number, HCT test spontaneous, while the content of CD3, CD4, CD8 lymphocytes is reduced, and CD25, CD16 is increased, at the local level (in the vaginal-cervical secretion of women and washings from the urethra of men) normalizes the concentration of IL-4 and IL-1β, and the concentration of TNF, IL-6, INFα is reduced compared to the norm.

When conducting treatment according to the developed method with the inclusion of derinate and MIL therapy, almost all indicators of the immune status were at the level of those in the group of healthy donors, with the exception of two indicators of nonspecific resistance at the local level (neutrophil stimulation index and spontaneous HCT test index) and cell content early activation markers (CD25 lymphocytes) (drawing).

Below are the results on the main indicators of the immune status, from which it can be seen that the positive values of the obtained numbers indicate the own effect of the proposed treatment regimen (Table 2)

Thus, the studies on the determined indicators of immunity in patients with herpes virus infection made it possible to determine the rating algorithm of immune disorders under the influence of various treatment methods, which shows that the proposed treatment regimen actually corrects almost all the studied parameters (except for the number of CD25 lymphocytes, HCT spontaneous test, stimulation index and functional reserve of neutrophils), in contrast to traditional treatment, where 16 indicators remain changed, and of leading the majority of patients were indicators corresponding to the second-third degree of immune deficiency.

Thus, the combination of derinat and MIL therapy, while correcting immunity disorders and significantly reducing clinical manifestations, is indicated in the treatment of patients with genital herpes in combination with chlamydia. As a result, in the process of treating patients, a high therapeutic effect was achieved, which improves their quality of life.

Clinical example. Patient P., 34 years old, complained of vesicular eruptions that appear on normal or slightly reddened edematous skin of the genital organs and perianal region, preceded by eruptions of itching, burning, tingling, pain in the inguinal-scrotal area. After 6 days, the bubbles burst, forming surface erosion. From the anamnesis of the disease, it was found that it suffers from genital herpes for about 5 years, the last 2 years there is a combination of herpes with chlamydia, relapses 2-3 times a year. The diagnosis is confirmed by the results of immunological blood tests. In the study of immune and cytokitic status: a reduced number of T-lymphocytes (0.83 × 10 ⁹ / L), T-helpers (0.82 × 10 ⁹ / L), a decrease in the Tx / Tc index (2.89), an increased content B-lymphocytes (0.71 × 10 ⁹ / L), Ig M (1.31 g / L), a decrease in the concentration of cytokines was detected in the urethra rinse: TNFα (22.8 pg / kg), IL-1β (24, 9 pkg / kg), IL-6 (35.9 pkg / kg), IL-4 (6.7 pkg / kg) and interferon-α (19.7 pkg / kg) (indicators were compared with the results of studies of healthy donors) .

The patient underwent a course of treatment by the proposed method, which included a combined method of using the drug Derinat and MIL exposure.

After the first week of the course, the patient noted the complete disappearance of pain, burning, itching. By the end of the course of treatment, lymphadenopathy disappeared, and a clear regression of herpetic eruptions was observed. When examining the immune status: the number of T-lymphocytes (1.02 × 10 ⁹ / L), T-helpers (0.91 × 10 ⁹ / L) increased, the Tx / Tc index (4.03) increased, the number of B- decreased lymphocytes (0.6 × 10 ⁹ / L), IgM (1.2 g / L) and increased concentrations of TNFα (53.6 pkg / kg), IL-1β (33.1 pkg / kg), IL-6 ( 57.6 pkg / kg), IL-4 (29.9 pkg / kg) and interferon-α (36.1 pkg / kg), that is, these indicators are much closer to the level of healthy individuals.

Therefore, the combination of Derinat and MIL-therapy, while correcting immunity disorders and providing a general strengthening effect, gives a high therapeutic effect.

Claims (1)

A method of treating patients with urogenital herpes virus infection in combination with chlamydia, characterized in that the patient is injected with a 1.5% solution of derinate in 5.0 ml intramuscularly 5 times after 48 hours, then a magneto-infrared laser effect on the thymus gland is carried out - 2 min, spleen - 2 min, inguinal lymph nodes - 2 min, lumbosacral - 2 min with a course of 10 daily procedures: wavelength 0.85-0.95 μm, pulse repetition rate 50 Hz, LED radiation power 50 mW, magnetic induction - 20-80 mT, dose of energy impact - 0.8-1.07 J / cm ² .